Evidence map›Paper›PMID 40221125›Full record

ArticleChemico-biological interactions2025

Synthesis of novel pyridazine and pyrimidine linked pyrazole derivatives as DNA ligase 1 and IV inhibitors that induce apoptosis.

S Aishwarya, Gabriela C Torres, Jose A Lopez-Saenz, Denisse A Gutierrez, Sujeet Kumar, Ashok Madarakhandi, Basavaraj Metikurki, Nishith Teraiya, Renato J Aguilera, Subhas S Karki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemico-biological interactions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S AishwaryaDepartment of Pharmaceutical Chemistry, KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education & Research-Belagavi), Rajajinagar, Bengaluru, Karnataka, 560010, India.
Gabriela C TorresCellular Characterization and Biorepository Core Facility, Border Biomedical Research Center, Department of Biological Sciences, College of Science, The University of Texas at El Paso, 500 West University Avenue, El Paso, TX, 79968-0519, USA.
Jose A Lopez-SaenzCellular Characterization and Biorepository Core Facility, Border Biomedical Research Center, Department of Biological Sciences, College of Science, The University of Texas at El Paso, 500 West University Avenue, El Paso, TX, 79968-0519, USA.
Denisse A GutierrezCellular Characterization and Biorepository Core Facility, Border Biomedical Research Center, Department of Biological Sciences, College of Science, The University of Texas at El Paso, 500 West University Avenue, El Paso, TX, 79968-0519, USA.
Sujeet KumarDepartment of Pharmaceutical Chemistry, NITTE College of Pharmaceutical Sciences, Yelahanka, Bengaluru, Karnataka 560064, India.
Ashok MadarakhandiDepartment of Pharmaceutical Chemistry, KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education & Research-Belagavi), Rajajinagar, Bengaluru, Karnataka, 560010, India.
Basavaraj MetikurkiDepartment of Pharmaceutical Chemistry, NITTE College of Pharmaceutical Sciences, Yelahanka, Bengaluru, Karnataka 560064, India.
Nishith TeraiyaDepartment of Pharmaceutical Chemistry, K B Institute of Pharmaceutical Education and Research, KadiSarvaVishvavidhyalaya, Gandhinagar, Gujarath, 382023, India.
Renato J AguileraCellular Characterization and Biorepository Core Facility, Border Biomedical Research Center, Department of Biological Sciences, College of Science, The University of Texas at El Paso, 500 West University Avenue, El Paso, TX, 79968-0519, USA. Electronic address: raguilera@utep.edu.
Subhas S KarkiDepartment of Pharmaceutical Chemistry, KLE College of Pharmacy (A Constituent Unit of KLE Academy of Higher Education & Research-Belagavi), Rajajinagar, Bengaluru, Karnataka, 560010, India. Electronic address: subhasskarki@gmail.com.

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Marc B Cox · 2019 to 2026
$35.1M
U-RISE at the University of Texas at El PasoT34GM145529 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2022 to 2024
$2.3M
Characterization of novel pyrazole compounds with potent anti-cancer activityR16GM149379 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI RENATO J AGUILERA · 2023 to 2026
$605k
NIGMS NIH HHS R16 GM149379NIGMS NIH HHS T34 GM145529NIMHD NIH HHS U54 MD007592
6 · The paper itself

Abstract

Human ligase I and ligase IV have recently been recognized as potential targets and regulators of cancer. Novel pyrazole analogues were synthesized and evaluated for their anti-proliferation effects against lymphoma, breast and other cancer cell lines. The initial biological investigation resulted in the identification of lead compounds 7a and 8e. Compounds 7a and 8e were the most cytotoxic to acute lymphoblastic leukemia CEM cells, with CC

Indexed as

Antineoplastic AgentsApoptosisDNA Ligase ATPEnzyme InhibitorsPyrazolesPyridazinesPyrimidinesCaspase 3Cell CycleCell Line, TumorCell ProliferationHumansMembrane Potential, MitochondrialMolecular Docking SimulationMolecular Dynamics SimulationReactive Oxygen SpeciesAntineoplastic AgentsCaspase 3DNA Ligase ATPEnzyme InhibitorsPyrazolespyridazinePyridazinespyrimidinePyrimidinesReactive Oxygen SpeciesApoptosisCell cycleCytotoxicityLeukemiaLigasesPyrazole

Identifiers

PMID40221125
PMCPMC12083462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.